Pharmacogenetics of glucose-lowering drug treatment: a systematic review (Q36982648)

17 August 2017

1 reference

title

Pharmacogenetics of glucose-lowering drug treatment: a systematic review (English)

1 reference

17 August 2017

3

Diederick E Grobbee

1 reference

17 August 2017

Ozlem Bozkurt

1

1 reference

17 August 2017

Anthonius de Boer

2

1 reference

17 August 2017

Eibert R Heerdink

4

1 reference

17 August 2017

Huib Burger

5

1 reference

17 August 2017

Olaf H Klungel

6

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Molecular Diagnosis and Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

11

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

291-302

1 reference

Causes and consequences of comorbidity: a review.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Oral antihyperglycemic therapy for type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Pharmacogenetics: potential for individualized drug therapy through genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The interface between pharmacoepidemiology and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Drug-gene interactions between genetic polymorphisms and antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Human lipoprotein lipase complementary DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Genetic cause of hyperglycaemia and response to treatment in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Frequency of cytochrome P450 2C9 mutant alleles in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Lack of Arg972 polymorphism in the IRS1 gene in Parakanã Brazilian Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Prime suspect: the TCF7L2 gene and type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Experimental models of transcription factor-associated maturity-onset diabetes of the young

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Lipoprotein lipase, a key role in atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

A genome-wide association study identifies novel risk loci for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

A tutorial on statistical methods for population association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Designing a multistage, SNP-based, genome screen for common diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Variants in the sulphonylurea receptor gene: association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation i

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256250

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

21 January 2018

1 reference

12 December 2020

Association of G-protein beta-3 subunit gene (GNB3) T825 allele with Type II diabetes

1 reference

12 December 2020

Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4

1 reference

12 December 2020

Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects

1 reference

12 December 2020

Polymorphism of the 3'-untranslated region of the leptin receptor gene, but not the adiponectin SNP45 polymorphism, predicts type 2 diabetes: a population-based study

1 reference

12 December 2020

Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

1 reference

12 December 2020

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

1 reference

12 December 2020

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

1 reference

12 December 2020

Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations

1 reference

12 December 2020

Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.

1 reference

12 December 2020

High sensitivity to sulphonylurea treatment in 2 patients with maturity-onset diabetes of the young type 3

1 reference

12 December 2020

Glycemic control and the risk of multiple microvascular diabetic complications.

1 reference

12 December 2020

Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes

1 reference

12 December 2020

Genetic analysis of the human cytochrome P450 CYP2C9 locus

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256250

1 reference

17 August 2017

1 reference